News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Biocryst Pharmaceuticals’s Influenza Drug Shows Promise in Study
July 17, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- BioCryst Pharmaceuticals said a late-stage study testing the intravenous form of its experimental influenza drug peramivir showed the drug was not inferior to another flu drug, Tamiflu.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
BioCryst Pharmaceuticals, Inc.
MORE ON THIS TOPIC
Cancer
Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial
November 20, 2026
·
3 min read
·
Gabrielle Masson
Alzheimer’s disease
Actinogen’s sole drug fails pivotal Alzheimer’s study, sinking stock 80%
November 19, 2026
·
1 min read
·
Gabrielle Masson
Approvals
Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
November 19, 2026
·
3 min read
·
Heather McKenzie
Insights
The untapped potential of drug repurposing
November 19, 2026
·
1 min read
·
Jennifer C. Smith-Parker